This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Vanoli, A Articles by Young, A. Search for Related Content PubMed PubMed Citation Articles by Vanoli, A Articles by Young, A. Social Bookmarking                         What's this?

Adequacy of venlafaxine dose prescribing in major depression and hospital resources implications

DDC, School of Applied Sciences, University of Northumbria, Newcastle upon Tyne, UK, alessandra.vanoli{at}northumbria.ac.uk

CJ Lane

Department of Psychiatry, University of British Columbia, Vancouver, BC, Canada

Claire Harrison

Psychological Services Directorate, Northumberland Tyne and Wear NHS Trust, Northumberland, UK

NI Steen

Centre for Health Services Research, University of Newcastle upon Tyne, Newcastle upon Tyne, UK

AH Young

Department of Psychiatry, Royal Victoria Infirmary, Newcastle upon Tyne, UK

Venlafaxine, a dual serotonin and noradrenaline re-uptake inhibitor, has been found to be effective at doses below 375 mg daily, but for patients with major depression higher doses can be required. In this retrospective naturalistic study, we investigated the effectiveness and resource implications of prescribing higher than standard doses of venlafaxine (tablet preparation). Ninety-six outpatients fulfilling DSM-IV criteria for major depressive disorder were assigned to two demographically matched cohorts: cohort A, receiving high doses (n = 38; doses 375 mg/day) and cohort B, receiving standard doses (n = 58; doses <375 mg/day). Data on hospital resources, drugs and medical profiles were extracted from patients' records. Information on cohort A was also obtained before their high-dose regime, while taking standard doses. A within-group analysis of cohort A showed that patients spent fewer days in hospital (P = 0.03) and had fewer outpatients visits (P < 0.01) when on high doses than when on standard doses. A between-group analysis found that cohort A, while on higher doses, had fewer outpatient visits compared with cohort B (P < 0.01). Patients in both groups had satisfactory drug tolerability and efficacy profiles. There were no differences between cohorts with regard to baseline characteristics, a part from the more intensive use of additional medications made by cohort A. Our preliminary investigation suggests that higher doses of venlafaxine may be cost-saving in relation to selected hospital resources. However, one cannot firmly conclude that the change in service use is due to the higher-dose regime, and we recommend further research to ascertain the cost-effectiveness of adequate dose prescribing in patients with poor symptom resolution at lower doses of venlafaxine.

Key Words: cost-consequences analysis • depressed patients • economics • high dose • non-responders • venlafaxine

Journal of Psychopharmacology, Vol. 22, No. 4, 434-440 (2008)
DOI: 10.1177/0269881107086178


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?